Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
touchIN CONVERSATION
Start Learning
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
CE/CME ACCREDITED
touchMDT
Start Learning
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
CE/CME ACCREDITED
JOURNALS
Start Learning
2024 AAD ANNUAL MEETING American Academy of Dermatology
touchMEETING HIGHLIGHTS
Start Learning
ADVENT symposia 2024: Updates in AD, PN and CSU
Sponsored content
CONFERENCE HUB
Start Learning
Insights from the CAMP-1 and CAMP-2 studies on cantharidin solution (0.7%) in molluscum contagiosum: James Del Rosso
JOURNALS
Start Learning
Breakthroughs in melanoma: Highlights from ASCO 2024
CONFERENCE HUB
Start Learning
Phase III SUNSHINE and SUNRISE trials investigating secukinumab in hidradenitis suppurativa: Afsaneh Alavi
CONFERENCE HUB
Start Learning
Barzolvolimab shows sustained efficacy over 52 weeks in antihistamine-refractory chronic spontaneous urticaria
JOURNALS
Start Learning
New study links rosacea with increased risk of malignant melanoma
touchPANEL DISCUSSION
Start Learning
Paediatric atopic dermatitis: Evolving strategies for improved management
CE/CME ACCREDITED

to view Favourites, Keep Notes and Track CME Credits

Favourites
Ruxolitinib cream shows safe and lasting control in paediatric atopic dermatitis
View
Paediatric atopic dermatitis: Evolving strategies for improved management
View
Barzolvolimab shows sustained efficacy over 52 weeks in antihistamine-refractory chronic spontaneous urticaria
View
Breakthroughs in melanoma: Highlights from ASCO 2024
View
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
View
Breaking new ground in CSU treatment: Highlights from EAACI 2024
View
Establishing treatment and care pathways for patients with prurigo nodularis: A patient-centric focus from multidisciplinary perspectives
View
Phase III SUNSHINE and SUNRISE trials investigating secukinumab in hidradenitis suppurativa: Afsaneh Alavi
View
Insights from the CAMP-1 and CAMP-2 studies on cantharidin solution (0.7%) in molluscum contagiosum: James Del Rosso
View
Honouring Prof. Marcus Maurer
View
In Partnership with...
Useful Links:
About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
Connect With Us:

Other websites from Touch Medical Media:

touchONCOLOGY
touchOPHTHALMOLOGY
touchENDOCRINOLOGY
touchNEUROLOGY
touchCARDIO
touchRESPIRATORY
touchIMMUNOLOGY
touchINFECTIOUS DISEASES
touchHAEMATOLOGY
touchDERMATOLOGY

Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

touchDERMATOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup